<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230514058176N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-19</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Hormone replacement therapy with ovarian stimulation as endometrial preparation protocols for frozen thawed embryo transfer</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Hormone replacement therapy with ovarian stimulation as endometrial preparation protocols for frozen thawed embryo transfer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>184</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70107</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study will be done in a randomized block fashion. Individual randomization unit is considered. RAS statistical software will be used for block randomization and also for determining the sequence of blocks. All patient information will be recorded in spss26 software.</study_design>
      <phase>N/A</phase>
      <hc_freetext>The method of endometrial preparation in the frozen embryo transfer cycle.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Infertile women referred to the infertility treatment center of Mahdieh Hospital, who are in the cycle of frozen embryo transfer, and in order to prepare the endometrium on the third day of menstruation, letrozole tablets (Latrax 2.5 mg, Aburihan Pharmaceuticals) were taken once a day at night for 5 days. Human menopausal gonadotropin (HMG 75 IU) ampoule will be injected intramuscularly once a day for three days. Then a control ultrasound is performed and if the follicle is 17 to 22 mm and the thickness of the endometrium is 6 to 7 mm, the human chorionic gonadotropin ampoule will be administered. (HCG 5000 IU) is injected intramuscularly. 36 hours later, 50 mg progesterone ampoule (Abourihan Company) will be injected intramuscularly for 3 days in the case of three-day-old embryos and 5 days in the case of 5-day-old embryos, and then embryo transfer is performed and two weeks after the transfer, a pregnancy test will be performed. Intervention 2: Control group:  Infertile women referred to the infertility treatment center of Mahdieh Hospital, who are in the cycle of frozen embryo transfer, who receive 2 mg estradiol pills (Aburihan Company) three times a day (every 8 hours) to prepare the endometrium on the third day of menstruation. one number) then a control ultrasound is performed and if the follicle reaches 17 to 22 mm and the endometrium thickness reaches 6 to 7 mm, 100 mg progesterone ampoule (Aburihan company) for 3 days in the case of 3-day and 5-day embryos In the case of 5-day-old embryos, the day is injected, and then embryo transfer is performed, and two weeks later, a pregnancy test is performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Samira Azimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shishe Gar khaneh Alley, Fadaian Islam Ave, Shoosh Sq, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1185817311</zip>
        <telephone>+98 21 5506 2628</telephone>
        <email>drazimi48@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Samia Azimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shishe Gar khaneh Alley, Fadaian Islam Ave, Shoosh Sq, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1185817311</zip>
        <telephone>+98 21 5506 2628</telephone>
        <email>drazimi48@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women referring to Mahdiyeh infertility treatment center aged between 18 and 42 years who have frozen embryos
Have a normal uterine structure
Have a healthy endometrium without endometrial polyps or submucosal myoma</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>42 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>anatomical malformation of uterus ; unicorn. bicorn
underlying disease like diabet. thyroid . cardiovascular. immun disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility associated with male factor</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Infertile women referred to the infertility treatment center of Mahdieh Hospital, who are in the cycle of frozen embryo transfer, and in order to prepare the endometrium on the third day of menstruation, letrozole tablets (Latrax 2.5 mg, Aburihan Pharmaceuticals) were taken once a day at night for 5 days. Human menopausal gonadotropin (HMG 75 IU) ampoule will be injected intramuscularly once a day for three days. Then a control ultrasound is performed and if the follicle is 17 to 22 mm and the thickness of the endometrium is 6 to 7 mm, the human chorionic gonadotropin ampoule will be administered. (HCG 5000 IU) is injected intramuscularly. 36 hours later, 50 mg progesterone ampoule (Abourihan Company) will be injected intramuscularly for 3 days in the case of three-day-old embryos and 5 days in the case of 5-day-old embryos, and then embryo transfer is performed and two weeks after the transfer, a pregnancy test will be performed.</i_keyword>
      <i_keyword>Control group:  Infertile women referred to the infertility treatment center of Mahdieh Hospital, who are in the cycle of frozen embryo transfer, who receive 2 mg estradiol pills (Aburihan Company) three times a day (every 8 hours) to prepare the endometrium on the third day of menstruation. one number) then a control ultrasound is performed and if the follicle reaches 17 to 22 mm and the endometrium thickness reaches 6 to 7 mm, 100 mg progesterone ampoule (Aburihan company) for 3 days in the case of 3-day and 5-day embryos In the case of 5-day-old embryos, the day is injected, and then embryo transfer is performed, and two weeks later, a pregnancy test is performed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Endometrial thickness: The appropriate thickness of the endometrial layer of the uterus for embryo transfer, which is better to be above 6 to 7 mm to prepare for embryo transfer. Timepoint: The thickness of the endometrium is measured before the start of the treatment and 7-14 days after the intervention. Method of measurement: Endometrial thickness is measured by transvaginal ultrasound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-30</approval_date>
        <contact_name>Ethic committee of Shahid Beheshti University of Medical Science</contact_name>
        <contact_address>Floor 13, Block A, Ministry of Health &amp; Medical Education Headquarters, Between Zarafashan &amp; South Falamak, Qods Town, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
